Glioblastoma Multiforme, Adult Clinical Trial
Official title:
UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly
The usual standard of care for patients over 65 diagnosed with glioblastoma ("GBM") or Grade 4 astrocytoma, IDH-mutant is a 3-week course of radiotherapy, with concurrent and adjuvant temozolomide (TMZ). This radiation dose and length of treatment are less than what would be given for younger patients, primarily due to unclear survival benefits from randomized trials. However, survival remains dismal, and may be partially due to the reduced radiation dose. Recent studies investigating this have found that increased radiation dose (to the equivalent of what is normally given over 6 weeks in younger patients) over 3 weeks is well-tolerated and has improved survival rates. Additionally, with the advent of novel technology such as the MR-Linac, adaptive radiotherapy with this regimen using reduced radiation margins is possible. Use of the MR-Linac allows for daily MRI scans to be done prior to treatment, so plans can be adapted to tumour dynamics and anatomical deformations. In this trial, we will examine the outcomes of increased radiation dose, combined with reduced-margin adaptive radiotherapy in this patient population.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04762069 -
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Recruiting |
NCT04869449 -
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
|
Early Phase 1 | |
| Withdrawn |
NCT03480867 -
Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)
|
Phase 1 | |
| Not yet recruiting |
NCT05653622 -
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT05954858 -
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
|
N/A | |
| Recruiting |
NCT05052957 -
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
|
Phase 2 | |
| Recruiting |
NCT05977738 -
Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin
|
Early Phase 1 | |
| Recruiting |
NCT04614909 -
Study of Pamiparib in Newly Diagnosed and rGBM
|
Early Phase 1 | |
| Recruiting |
NCT06283927 -
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
|
||
| Recruiting |
NCT06146725 -
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
|
||
| Recruiting |
NCT06146738 -
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
|
||
| Recruiting |
NCT06118723 -
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
|
||
| Recruiting |
NCT04825275 -
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
|
Early Phase 1 | |
| Recruiting |
NCT05333588 -
The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
|
Early Phase 1 | |
| Completed |
NCT05671016 -
Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy
|
||
| Recruiting |
NCT05271240 -
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
|
Phase 3 | |
| Recruiting |
NCT04469699 -
Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT05720078 -
UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)
|
N/A |